Triple Regulator (TIA-39-C20)

Triple Regulator (TIA-39-C20) (12mg)

Peptide Receptor Modulator Research Series – Single, Dual, and Triple Agonist Investigational Compounds.

Product Specifications
CAS Number	2381089-83-2
Molecular Formula	C221H342N46O68
Molecular Weight (g/mol)	4731.33
Amino Acid Count	39
Amino Acid Sequence	H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(γ-Glu-(AEEA)-C20-diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Purity	≥99% by HPLC \| COA available
Physical Form	Lyophilized powder
Solubility	Soluble in bacteriostatic water; consult COA for specific solvent recommendations
Storage Conditions	Store at -20°C; protect from light and moisture; reconstitute with bacteriostatic water

For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures.

This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.

Published Literature
+

#	Reference	Link
[01]	Jastreboff A.M., Aronne L.J., Ahmad N.N., et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 2022;387:205–216.	NEJM PubMed
[02]	Garvey W.T., Frias J.P., Jastreboff A.M., et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes: SURMOUNT-2. Lancet. 2023;402(10402):613–626.	PubMed
[03]	Wadden T.A., Chao A.M., Machineni S., et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: SURMOUNT-3. Nature Medicine. 2023;29:2909–2918.	PubMed Journal
[04]	Aronne L.J., Sattar N., Horn D.B., et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4. JAMA. 2024;331(1):38–48.	PubMed Full Text
[05]	Frias J.P., Davies M.J., Rosenstock J., et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 2021;385:503–515.	PubMed NEJM
[06]	Del Prato S., Kahn S.E., Pavo I., et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk: SURPASS-4. Lancet. 2021;398(10313):1811–1824.	PubMed
[07]	Malhotra A., Grunstein R.R., Fietze I., et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 2024;391:1193–1205.	PubMed NEJM
[08]	Loomba R., Hartman M.L., Lawitz E.J., et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 2024;391:299–310.	PubMed NEJM
[09]	Jastreboff A.M., le Roux C.W., Stefanski A., et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 2025;392:958–971.	PubMed NEJM
[10]	Aronne L.J., Sattar N., Horn D.B., et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 2025.	PubMed NEJM

Receptor Binding Profile
+

Compound	Primary Receptor Target	Binding / Activity Profile	Reported Potency / Affinity	Functional Effect
Retatrutide	GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR)	Triple hormone receptor agonist; binds to and activates GIPR, GLP-1R, and GCGR, with stronger reported activity at GIPR compared with GLP-1R and GCGR	Human receptor EC50 values reported: GIPR: 0.0643 nM; GLP-1R: 0.775 nM; GCGR: 5.79 nM	Activates multi-receptor incretin and glucagon signaling pathways associated with glucose regulation, reduced calorie intake through GIPR/GLP-1R pathways, and increased energy expenditure through GCGR activity in pharmacology studies (sciencedirect.com)

Dose	10mg, 12mg, 24mg, 60mg

Triple Regulator (TIA-39-C20) (12mg)

Related products

Login